These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 24739484)
1. Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Higashihara E; Nutahara K; Tanbo M; Hara H; Miyazaki I; Kobayashi K; Nitatori T Nephrol Dial Transplant; 2014 Sep; 29(9):1710-9. PubMed ID: 24739484 [TBL] [Abstract][Full Text] [Related]
2. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953 [TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Torres VE; King BF; Chapman AB; Brummer ME; Bae KT; Glockner JF; Arya K; Risk D; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Meyers CM; Zhang X; Thompson PA; Miller JP; Clin J Am Soc Nephrol; 2007 Jan; 2(1):112-20. PubMed ID: 17699395 [TBL] [Abstract][Full Text] [Related]
4. Kidney volume and function in autosomal dominant polycystic kidney disease. Higashihara E; Nutahara K; Okegawa T; Shishido T; Tanbo M; Kobayasi K; Nitadori T Clin Exp Nephrol; 2014 Feb; 18(1):157-65. PubMed ID: 23864346 [TBL] [Abstract][Full Text] [Related]
5. Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis? Casteleijn NF; Zittema D; Bakker SJ; Boertien WE; Gaillard CA; Meijer E; Spithoven EM; Struck J; Gansevoort RT Am J Nephrol; 2015; 41(3):248-56. PubMed ID: 25926129 [TBL] [Abstract][Full Text] [Related]
6. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Boertien WE; Meijer E; Li J; Bost JE; Struck J; Flessner MF; Gansevoort RT; Torres VE; Am J Kidney Dis; 2013 Mar; 61(3):420-9. PubMed ID: 23089511 [TBL] [Abstract][Full Text] [Related]
7. A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease. Simms RJ; Doshi T; Metherall P; Ryan D; Wright P; Gruel N; van Gastel MDA; Gansevoort RT; Tindale W; Ong ACM Eur Radiol; 2019 Aug; 29(8):4188-4197. PubMed ID: 30666443 [TBL] [Abstract][Full Text] [Related]
16. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease. Lacquaniti A; Chirico V; Lupica R; Buemi A; Loddo S; Caccamo C; Salis P; Bertani T; Buemi M Peptides; 2013 Nov; 49():1-8. PubMed ID: 23973863 [TBL] [Abstract][Full Text] [Related]
17. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course. Kim K; Trott JF; Gao G; Chapman A; Weiss RH BMC Nephrol; 2019 Feb; 20(1):66. PubMed ID: 30803434 [TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease. Chen D; Ma Y; Wang X; Yu S; Li L; Dai B; Mao Z; Sun L; Xu C; Rong S; Tang M; Zhao H; Liu H; Serra AL; Graf N; Liu S; Wüthrich RP; Mei C PLoS One; 2014; 9(3):e92232. PubMed ID: 24651850 [TBL] [Abstract][Full Text] [Related]